08.05.22 -- Solutions For Your Small Molecule API & Drug Product Projects

Taste, smell, and mouthfeel are the key product features to address when developing pediatric formulations. Incremental formulation and clinical research require cost-effective solutions with flexibility in manufacturing scale.

Our dedication to quality and safety of energetic chemistry has laid a solid foundation for supplying cGMP high energy compounds to world-leading pharmaceutical companies.

According to recent market surveys the global blister packaging market reached a value of US$ 22.7 Billion in 2021. Looking forward, the market to reach US$ 32.2 Billion by 2027, exhibiting a CAGR of 5.8% during 2022-2027.

Dr. Bert Metten, Tech. Dev. Manager at Ajinomoto Bio-Pharma Services, explores dangerous chemistries and continuous flow processes for the manufacture of safe, efficacious, cost-effective products.

Asymchem offers a superior mix of CDMO solutions today while continually driving new innovations to give you a greater advantage tomorrow. See what our KNOW-HOW can do for your development needs.

Ascendia specializes in the development of market suitable formulations for poorly water soluble drug substances. Based on the pre-formulation data package and the delivery requirements for the product, we recommend a comprehensive formulation development strategy. We understand that each formulation is unique and must address the specific challenges associated with poor solubility, inadequate bioavailability, and/or unacceptable physical/chemical stability. We also understand the urgency companies have for progressing their pipeline, and our approach maximizes the probability of success by exploring multiple formulation options in parallel if necessary.

Learn how controlled and modified release can provide improved compliance and therapeutic effectiveness with right release profile based on API properties, PK challenges, and patient needs.

We have 50 years of experience developing, manufacturing and marketing oral and injectable-non-sterile APIs (NCEs and generics) for regulated markets.

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics and small molecules to meet the goals of patient-centric therapies, improved medicine and better healthcare economics.

The market for oral drug products with an immediate release profile continues to move towards the development of more complex dosage forms designed to address specific functional or application requirements. While each formulation is different, customers most commonly want solutions to some combination of these five key challenges.